| Document |
Document Title |
|
WO/2022/226667A1 |
The present application relates to substituted heterocyclic compounds of Formula (I) and substituted compound of Formula (II): (I) (II) or pharmaceutically acceptable salts, solvates and/or prodrugs thereof, to compositions comprising th...
|
|
WO/2022/232004A1 |
Provided are compounds of Formula (I): and pharmaceutically acceptable salts and compositions thereof, which are useful for treating a variety of conditions associated with TREX1.
|
|
WO/2022/232333A1 |
Described herein are compounds of Formula (I) or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R5, L, X and Y are as defined herein. The compounds of Formula (I) act as IL4I1 inhibitors and can be useful in preventi...
|
|
WO/2022/226660A1 |
The present disclosure relates to methods of preventing or treating parasite infection in a plurality of fish in need thereof, comprising administering to the fish an effective amount of an isoxazoline such as fluralaner, a composition c...
|
|
WO/2022/228490A1 |
Disclosed are a polycyclic derivative modulator, and a preparation method therefor and the use thereof. Specifically, disclosed are a compound as represented by general formula (I-D), a preparation method therefor, a pharmaceutical compo...
|
|
WO/2022/232588A1 |
The present disclosure relates to a biodegradable ocular implant comprising a biodegradable polymer containing a compound such as Edonentan, or a pharmaceutically acceptable salt thereof. Also disclosed are methods of treatment of ocular...
|
|
WO/2022/227015A1 |
Described herein are compounds of Formula I or a pharmaceutically acceptable salt thereof. The compounds of Formula I act as IL4I1 inhibitors and can be useful in preventing, treating or acting as a remedial agent for IL4I1-related disea...
|
|
WO/2022/228549A1 |
The present disclose includes, among other things, compounds that treat or lessen the severity of a disorder, pharmaceutical compositions and methods of making and using the same.
|
|
WO/2022/226655A1 |
Methods of treating cancers having a biallelic ATM loss of function mutation are disclosed. Also disclosed are methods of inducing cell death in cancer cells having a biallelic ATM loss of function mutation. The methods typically include...
|
|
WO/2022/226668A1 |
The present application relates to halo-substituted heterocyclic compounds of Formula (I): or pharmaceutically acceptable salts, solvates and/or prodrugs thereof, to compositions comprising these compounds or pharmaceutically acceptable ...
|
|
WO/2022/230912A1 |
The present invention addresses the problem of providing a pharmaceutical composition, in particular, a compound suitable for preventing and/or treating inflammatory diseases and/or neurodegenerative diseases. The present inventors hav...
|
|
WO/2022/231872A1 |
Disclosed herein are compounds and compositions useful for preventing and/or treating a neurological disorder, a disorder associated with excessive neuronal excitability, or a disorder associated with a gain-of-function mutation in a gen...
|
|
WO/2022/226665A1 |
The present application relates to halo-substituted aza-heteroaryl compounds of Formula (I): (I) or pharmaceutically acceptable salts, solvates and/or prodrugs thereof, to compositions comprising these compounds or pharmaceutically accep...
|
|
WO/2022/232088A1 |
Provided herein are compounds of Formula (I'), Formula (II), Formula (III), Formula (IV), Formula (V), Formula (VI), Formula (VII), or Formula (VIII) and pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tau...
|
|
WO/2022/228413A1 |
Disclosed in the present invention are an RIPK1 inhibitor for inhibiting programmed cell death and a preparation method therefor. The RIPK1 inhibitor of the present invention is as represented by general formula I, wherein X, Y, Z, L, R1...
|
|
WO/2022/229405A1 |
The present invention relates to new pyridine-sulfonamide derivatives of formula (I') as sigma ligands having a great affinity for sigma receptors, especially the sigma-1 receptor (σ1) and/or sigma-2 receptor (σ2), as well as to the pr...
|
|
WO/2022/223689A1 |
The invention relates to novel compounds of the general formula (I), which are characterized in that at least one of the groups A and B contains at least 3 rings, pharmaceutical compositions comprising them and the use thereof as medicam...
|
|
WO/2022/223554A1 |
The present invention relates to new 1H-pyrazole derivatives of formula (I) as sigma ligands having a great affinity for sigma receptors, especially the sigma-1 receptor (σ1) and/or sigma-2 receptor (σ2), as well as to the process for ...
|
|
WO/2022/225914A1 |
The present disclosure provides GLP-1R agonists, and compositions, methods, and kits thereof. Such compounds are generally useful for treating a GLP-1R mediated disease or condition in a human.
|
|
WO/2022/223750A1 |
The invention provides new heterocyclic compounds having the general formula (I), wherein A, B, X, and R1 to R7 are as described herein, compositions including thecompounds, processes of manufacturing the compounds and methods of using t...
|
|
WO/2022/222730A1 |
Disclosed in the present invention are a compound with mother nucleus of 3-phenyl-1,2,4-oxadiazole, a preparation method therefor and an application thereof. The compound with mother nucleus of 3-phenyl-1,2,4-oxadiazole provided in the p...
|
|
WO/2022/224924A1 |
The present invention addresses the problem of providing: a nitrogen-containing heteroaryl compound which exhibits excellent bactericidal and anti-bacterial activity and excellent safety and which can be synthesized in an industrially ad...
|
|
WO/2022/224223A1 |
Provided herein are compounds of formula (I) and compositions for treating, managing or preventing coronaviral related diseases. In particular, provided herein are cyclic dione compounds which are inhibitors of SARS-CoV-2 main protease (...
|
|
WO/2022/225312A1 |
The present invention relates to a novel oxazolidinone derivative, a method for preparing same, and a herbicide comprising the compound. The compound of the present invention has high safety for wheat or corn and excellent herbicidal act...
|
|
WO/2022/224166A1 |
The present invention generally discloses compounds having LXR (the liver X receptor) agonistic activity, to the use of such compounds in the treatment of various disorders such as proliferative disorders, Alzheimer's disease, inflammato...
|
|
WO/2022/225941A1 |
The present disclosure provides GLP-1R agonists, and compositions, methods, and kits thereof. Such compounds are generally useful for treating a GLP-1R mediated disease or condition in a human.
|
|
WO/2022/218399A1 |
Disclosed are a central chirality induced spiro chiral tetradentate cyclometalated platinum (II) and palladium (II) complex-based circularly polarized luminescence material and an application thereof. Spiro chiral metal complex molecules...
|
|
WO/2022/218289A1 |
This disclosure relates to heterobifunctional compounds (e.g., bi-functional small molecule compounds), compositions comprising one or more of the heterobifunctional compounds, and to methods of use the heterobifunctional compounds for t...
|
|
WO/2022/219013A1 |
The present disclosure provides certain uracil derivatives that are inhibitors of transient receptor potential ankyrin 1 (TRPA1), and are therefore useful for the treatment of diseases treatable by inhibition of TRPA1. Also provided are ...
|
|
WO/2022/221194A1 |
Disclosed herein are inhibitors of TACC and methods of treating certain diseases and disorders (e.g., diseases and disorders related to TACC).
|
|
WO/2022/218429A1 |
The present application relates to a bicyclic substituted aromatic carboxylic acid compound, and in particular to a compound as represented by formula (I) and a pharmaceutically acceptable salt thereof. In formula (I), R2 and R3 and atom...
|
|
WO/2022/219546A1 |
The present application relates to Leukotriene A4 hydrolase (LTA4H) inhibitors of formula (I), for use in the treatment of various disorders.
|
|
WO/2022/219146A2 |
Compounds of formula (I) wherein the substituents are as defined in claim 1, and the agrochemically acceptable salts stereoisomers, enantiomers, tautomers and N-oxides of those compounds, can be used as insecticides.
|
|
WO/2022/216097A1 |
The present invention relates to: a novel leucine-rich repeat kinase 2 (LRRK2) inhibitor of chemical formula 1; a pharmaceutical composition containing same for preventing or treating LRRK2-mediated or -related diseases or disorders; and...
|
|
WO/2022/189856A9 |
This invention provides compounds, for example, of Formulae (A)-(H) and (J)-(AA) and pharmaceutically acceptable salts, solvates, esters, amides, and prodrugs thereof. The invention further provides pharmaceutical compositions comprising...
|
|
WO/2022/215020A1 |
The present invention relates to a novel 1,3,4-oxadiazole thiocarbonyl compound having a histone deacetylase 6 (HDAC6) inhibitory activity, stereoisomers thereof, pharmaceutically acceptable salts thereof, a use thereof for preparing a m...
|
|
WO/2022/216094A1 |
The present invention relates to: a novel compound having excellent GLP-1 agonist activity and an excellent DMPK profile, and thus useful as an agent for treating or preventing obesity or various metabolic diseases such as diabetes and h...
|
|
WO/2022/216709A1 |
This disclosure is directed, at least in part, to GPR119 agonists useful for the treatment of conditions or disorders involving the gut-brain axis. In some embodiments, the GPR119 agonists are gut-restricted compounds. In some embodiment...
|
|
WO/2022/214377A1 |
Compounds of the formula (I) wherein the substituents are as defined in claim 1, useful as a pesticides, especially as herbicides.
|
|
WO/2022/214606A1 |
The present invention relates to compounds of formula (I) or salts, solvates, cocrystals, tautomers, or mixtures thereof. Furthermore, the present invention relates to pharmaceutical compositions comprising said compounds. Moreover, the ...
|
|
WO/2022/217232A1 |
Provided herein are compounds, pharmaceutical compositions, and methods of use thereof, including methods of treating a neurological or psychiatric disease or disorder. For example, provided herein is a compound of Formula I: (I) or a ph...
|
|
WO/2022/216655A1 |
The present invention relates to (6-((octahydrocyclopenta[c]pyrrol-5- yl)amino)pyridazin-3-yl)benzamide (R2b is -C(O)N(RA1)(RA2) and N- (6-((octahydrocyclopenta[c]pyrrol-5-yl)amino)pyridazin-3-yl)
phenyl) carboxamide (R2b is -N(RB)C(O)R...
|
|
WO/2022/214531A1 |
The present invention relates to new compounds of formula (I) as sigma ligands having a great affinity for sigma receptors, sigma-1 receptor (σ1) and/or sigma-2 receptor (σ2). The present invention also refers to the process for the pr...
|
|
WO/2022/216098A1 |
The present invention relates to: a novel leucine-rich repeat kinase 2 (LRRK2) inhibitor of chemical formula 1; a pharmaceutical composition for the prevention or treatment of diseases or disorders mediated by or associated with LRRK2, t...
|
|
WO/2022/214869A2 |
Described herein are compounds that are ULK1/2 inhibitors and their use in the treatment of disorders such as cancers.
|
|
WO/2022/207752A1 |
A compound comprising the formula (I), wherein each X1 is independently selected from C, N, O and S; each Y is independently selected from C and N; Z1 is independently selected from C and N; each X1 may independently be unsubstituted, or...
|
|
WO/2022/205587A1 |
Disclosed in embodiments of the present invention are an organic compound and a production method therefor, and a display panel. The general formula of the organic compound is (I), wherein Ar includes any one of or a combination of some ...
|
|
WO/2022/207496A1 |
The present invention relates to 3-(hetero)aryl-5-chlorodifluoromethyl-1,2,4-oxadiazole compounds as well as the uses thereof for controlling harmful microorganisms, in particular phytopathogenic fungi, in crop protection.
|
|
WO/2022/207494A1 |
The present invention relates to 3-(hetero)aryl-5-chlorodifluoromethyl-1,2,4-oxadiazole compounds as well as the uses thereof for controlling harmful microorganisms, in particular phytopathogenic fungi, in crop protection.
|
|
WO/2022/211595A1 |
The present invention relates to a pharmaceutical composition for the prevention and treatment of a ketohexokinase-related metabolic disease comprising at least one of a novel oxadiazole compound represented by chemical formula I, an iso...
|
